Anticancer Therapies – News and Features
Drug Targeting “Stressed” Cancer Cells Shows Promise in Trial
In a clinical trial, a new drug prevented cancer growth in terminally ill patients, with 70% of those who received the medicine becoming stable after six weeks.
Physical Activity May Prevent Colon Cancer Returning
New research has found that physical activity can prevent, and not just delay, cancer recurrence in patients previously treated for colon cancer.
Could Lymph Nodes Improve Cancer Immunotherapy Success?
New data suggests immunotherapies may activate lymph nodes to produce tumor-fighting T cells.
Nanotechnology Could Aid Drug Delivery for Lymphedema
By using nanotechnology to repair the pumping action of lymphatic vessels, Georgia Institute of Technology researchers have developed a unique approach to treating lymphedema.
Improved Bone Tumor Model Boosts Search for Therapies
Researchers have developed and used an upgraded tumor model that mimics bone to find that the body’s immune response can make tumor cells more resistant to chemotherapy.
Key Source of T-Cell “Exhaustion” Identified
In a new study, scientists show the commanding role of a specialized group of proteins in the nuclei of our cells, called mSWI/SNF (or BAF) complexes, both in activating T cells to attack cancer and triggering exhaustion.
New Biomarkers Could Be “More Accurate” Predictors of Pancreatic Cancer
A new study identifies a set of biomarkers that could help clinicians to predict whether pancreatic cysts will remain benign or develop into cancer.
Resistance Mechanisms to KRAS Inhibitor in Lung Cancer Identified
A new study reveals the mechanisms responsible for the development of tumor resistance to a new drug, the first approved inhibitor against the KRAS oncogene.
New Drug Combination Reduces Lung Tumors in Mice
A targeted therapy that combines two different drugs has been shown to be effective at reducing the size and number of non-small cell lung cancer tumors in mice.
How a Class of Cancer Drugs Causes Inflammatory Side Effects Discovered
The mechanism behind how tyrosine kinase inhibitors – a class of cancer drug – cause serious inflammatory side effects has been revealed by a new study.